Semax is part of the FDA advisory committee peptide discussion set.
Evidence level: Primary regulatory
Sources: U.S. Food and Drug Administration
Use this as the page anchor until more sources are reviewed.
Research peptide
Semax
Semax is often discussed online in cognitive and performance contexts. The index treats it as a source-backed watch item until regulatory and primary-source records are reviewed.
Regulatory watch
Last reviewed 2026-07-03
Next review 2026-07-24
Evidence snapshot
Do not expand online cognitive claims without specific source support and review notes.
Scheduled for FDA advisory committee discussion in July 2026.
Frequently discussed in media and community contexts.
Needs claim-level source mapping before broader coverage.
Tracked claims
Russian-language clinical publications describe cognitive and attention-enhancing effects of Semax, but these studies lack independent Western replication.
Evidence level: Peer reviewed
Sources: PubMed / NCBI
Semax is a heptapeptide ACTH analog registered as a medicine in Russia. Studies are primarily from Russian institutions and have not been replicated in Western clinical trials.
Semax is discussed in biohacking communities as a cognitive enhancer despite its lack of FDA approval or regulatory recognition outside Russia.
Evidence level: Community discussion
Sources: PubMed / NCBI, U.S. Food and Drug Administration
Track community cognitive-enhancement claims as source-discovery signals. The FDA bulk risk list applies to compounded peptide products marketed in the United States.
Free report
Get the source-quality checklist
Use the same checklist Peptide Report uses to separate Semax claims, source records, supplier documentation, and media signals.
V1 collects email, role, and topic interest only. No medication, health-condition, dosing, or current-use data is collected in this form.
Sources on this page
Source records are stored in the repo and linked from each claim.
July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting
FDA advisory committee meeting notice listing multiple peptide bulk substances scheduled for discussion.
Certain bulk drug substances for use in compounding may present significant safety risks
FDA page summarizing bulk drug substances that may present significant safety risks in compounding contexts.
Semax: cognitive and attention effects in clinical and preclinical studies
Russian-language clinical and preclinical publications on Semax (a heptapeptide ACTH analog) describing cognitive and attention-enhancing effects. Studies are primarily from Russian institutions and lack independent Western replication.
Related compounds
BPC-157
BPC-157 is widely discussed online in injury recovery and performance communities, but the public evidence and regulator...
Regulatory watchDSIP
DSIP appears in online sleep and recovery discussions. This page tracks the topic as a source-backed index entry pending...
Regulatory watchEpitalon
Epitalon is often discussed in longevity-oriented peptide content. The page starts as a regulatory watch entry and shoul...
Regulatory watchKPV
KPV is a peptide topic appearing in online wellness and research discussions. This page tracks the public source record ...
Regulatory watchStay informed